Sensing technology and adaptive deep brain stimulation (DBS) have recently entered clinical practice, enabling continuous tracking of basal ganglia local field potentials (LFPs) and real-time adjustment of stimulation.1-5 Current adaptive DBS strategies rely on beta-band activity,6, 7 an established biomarker in Parkinson's disease (PD) that reflects dopaminergic state8-10 and motor impairment.11-14 The PD symptom spectrum also includes numerous sleep disturbances such as insomnia, nocturnal...
